Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized anti-HER2 antibody linked to a topoisomerase I (TOP1) inhibitor
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) ; Topoisomerase I (TOP1)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today